Menu

雷帕鸣(西罗莫司片)怎么吃

Author: Medicalhalo
Release time: 2025-10-19 11:44:20

It is suitable for patients aged 13 or above who have received kidney transplants to prevent organ rejection. Recommended for use in combination with cyclosporine and corticosteroids.

How to take Rapamin (sirolimus tablets)?

The recommended way of taking rapamycin (sirolimus tablets, sirolimus) is: orally, once a day. It should be started as soon as possible after transplantation. For new transplant recipients, the loading dose that should be taken for the first time is three times the maintenance dose. The recommended loading dose of sirolimus for kidney transplant patients is 6 mg and the maintenance dose is 2 mg/day.

  Although the loading dose of 15 mg and the maintenance dose of 5 mg/day used in clinical trials are safe and effective, the therapeutic benefits of doses above 2 mg are unclear for kidney transplant patients. The overall safety profile of patients taking rapamycin (sirolimus tablets, sirolimus) 2 mg daily is better than that of patients taking rapamin sirolimus tablets 5 mg daily.

It should be noted that allergic reactions, including angioedema, exfoliative dermatitis and hypersensitivity vasculitis, have been reported during the treatment of rapamin (sirolimus tablets). When patients experience the above reactions, they should stop taking the drug and seek medical treatment immediately. Because immunosuppression may also increase the risk of infection, including activation of latent viral infections (including BK virus-related nephropathy), fatal infections, and sepsis, patients need to take precautions against related diseases after taking rapamycin (sirolimus).

  Taking it for treatment may cause hyperlipidemia, which may increase blood lipids (cholesterol and triglycerides). Patients with hyperlipidemia should use this drug with caution. Patients should monitor cholesterol/lipids while receiving sirolimus; if hyperlipidemia occurs, follow current management guidelines (diet, exercise, lipid-lowering agents). Antihyperlipidemic treatments may not be effective in achieving normal levels.

Recommended related hot articles: /newsDetail/82392.html

[ 免责声明 ]  本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。